PMID- 1351679
OWN - NLM
STAT- MEDLINE
DCOM- 19920721
LR  - 20190501
IS  - 0027-8424 (Print)
IS  - 1091-6490 (Electronic)
IS  - 0027-8424 (Linking)
VI  - 89
IP  - 12
DP  - 1992 Jun 15
TI  - ERBB2 amplification in breast cancer analyzed by fluorescence in situ 
      hybridization.
PG  - 5321-5
AB  - We illustrate the use of fluorescence in situ hybridization (FISH) for analysis 
      of ERBB2 oncogene copy number, the level of amplification (here defined as the 
      ratio of ERBB2 copy number to copy number of chromosome 17 centromeres), and the 
      distribution of amplified genes in breast cancer cell lines and uncultured 
      primary breast carcinomas. The relative ERBB2 copy number determined by FISH in 
      10 breast cancer cell lines correlated strongly with Southern blot results (r = 
      0.98) when probes for an identical reference locus were used in the two methods. 
      Metaphase analysis of cell lines showed that amplified ERBB2 copies always 
      occurred in intrachromosomal clusters but that the number and chromosomal 
      location of these clusters varied among the cell lines. In interphase nuclei of 
      primary tumors showing ERBB2 amplification (10/44), ERBB2 copies were seen as one 
      to four clusters, also suggesting intrachromosomal localization. Regardless of 
      the average level of amplification, all these tumors contained highly amplified 
      cell subpopulations with at least 25, and sometimes more than 100, ERBB2 copies 
      per cell. Tumors that did not show amplification by FISH (34/44) had an average 
      of one to five ERBB2 copies scattered randomly in the nuclei and completely 
      lacked cells with high copy levels. FISH results on primary tumors were 
      concordant with slot blot results on amplification and with immunohistochemical 
      detection of overexpression. Quantitative analysis of ERBB2 amplification by FISH 
      may improve prognostic assessments based on the pattern of amplification and 
      detection of heavily amplified tumor cell subpopulations.
FAU - Kallioniemi, O P
AU  - Kallioniemi OP
AD  - Department of Laboratory Medicine, University of California, San Francisco 
      94143-0808.
FAU - Kallioniemi, A
AU  - Kallioniemi A
FAU - Kurisu, W
AU  - Kurisu W
FAU - Thor, A
AU  - Thor A
FAU - Chen, L C
AU  - Chen LC
FAU - Smith, H S
AU  - Smith HS
FAU - Waldman, F M
AU  - Waldman FM
FAU - Pinkel, D
AU  - Pinkel D
FAU - Gray, J W
AU  - Gray JW
LA  - eng
GR  - CA 44768/CA/NCI NIH HHS/United States
GR  - CA 45919/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Proc Natl Acad Sci U S A
JT  - Proceedings of the National Academy of Sciences of the United States of America
JID - 7505876
RN  - 0 (Oncogene Proteins, Viral)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
GS  - ERBB2
MH  - Breast Neoplasms/*genetics
MH  - Cell Line
MH  - Cell Nucleus/physiology/ultrastructure
MH  - Female
MH  - Fluorescent Antibody Technique
MH  - *Gene Amplification
MH  - Humans
MH  - Interphase
MH  - Metaphase
MH  - Nucleic Acid Hybridization
MH  - Oncogene Proteins, Viral/*genetics
MH  - *Oncogenes
MH  - Receptor, ErbB-2
PMC - PMC49283
EDAT- 1992/06/15 00:00
MHDA- 1992/06/15 00:01
PMCR- 1992/12/15
CRDT- 1992/06/15 00:00
PHST- 1992/06/15 00:00 [pubmed]
PHST- 1992/06/15 00:01 [medline]
PHST- 1992/06/15 00:00 [entrez]
PHST- 1992/12/15 00:00 [pmc-release]
AID - 10.1073/pnas.89.12.5321 [doi]
PST - ppublish
SO  - Proc Natl Acad Sci U S A. 1992 Jun 15;89(12):5321-5. doi: 
      10.1073/pnas.89.12.5321.